Literature DB >> 17454881

Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study).

Magne Henriksen1, Jørgen Jahnsen, Idar Lygren, Erling Aadland, Tom Schulz, Morten H Vatn, Bjørn Moum.   

Abstract

BACKGROUND: There are few population-based, prospective studies on the clinical course in patients with Crohn's disease (CD). AIM: To extend the observation period in a population-based prospective study (the IBSEN study) to find out more about the initial 5-year clinical course in CD patients and to relate the findings to the Vienna classification.
METHODS: All patients diagnosed with inflammatory bowel disease (IBD) in southeastern Norway in the 4 years 1990-1993 were followed prospectively. The patients were invited to a systematic follow-up visit at their local hospital 1 and 5 years after inclusion in the study. The visits included a structured interview, a clinical examination and colonoscopy.
RESULTS: Out of 843 patients initially diagnosed with IBD, 200 patients with definite CD were alive and had sufficient data for analysis 5 years after diagnosis. Changes in disease localization and behaviour in relation to the Vienna classification were observed in 27 (13.5%) and 35 patients (17.5%), respectively. During the observation period, 56 patients (28%) underwent surgery with intestinal resection, and half of these had disease localized in the terminal ileum. At the time of the 5-year visit, oral sulfasalazin and 5-aminosalicylic acid (5-ASA) were the most frequently used medications (by 54% of the patients), while oral glucocorticosteroids and azathioprine were being used by 25% and 13%, respectively. Seventy-two percent of the patients had taken oral glucocorticosteroids at some time in the course of the 5-year period. The majority of the patients had intestinal symptoms at 5 years, but only 16% had symptoms that interfered with everyday activities. Fourteen percent of the patients had had a relapse-free 5-year course; however, relapse was not related to the initial Vienna classification. When the patients described the clinical course, 44% reported an improvement in symptoms during the follow-up period.
CONCLUSIONS: The 5-year clinical course in an unselected cohort of CD patients was mostly mild. The frequency of surgery was lower than that observed in other studies and only a minority of the patients had symptoms that interfered with everyday activities 5 years after the initial diagnosis. The Vienna classification predicted the risk of surgery, but did not predict symptoms at 5 years, relapses during the observation period or the course of disease as described by the patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17454881     DOI: 10.1080/00365520601076124

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  42 in total

1.  Framework for assessing quality of care for inflammatory bowel disease in Sweden.

Authors:  Martin Rejler; Jörgen Tholstrup; Mattias Elg; Anna Spångéus; Boel Andersson Gäre
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

2.  Medical management of Crohn's disease.

Authors:  Paul A Feldman; Daniel Wolfson; Jamie S Barkin
Journal:  Clin Colon Rectal Surg       Date:  2007-11

3.  Ulcerative colitis: Natural history--an optimistic message from Norway.

Authors:  Laurent Peyrin-Biroulet; Jean-Frederic Colombel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07       Impact factor: 46.802

Review 4.  Surgery for Crohn's disease in the era of biologicals: a reduced need or delayed verdict?

Authors:  Anthony de Buck van Overstraeten; Albert Wolthuis; André D'Hoore
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

5.  Recent Research in IBD Epidemiology.

Authors:  Morten H Vatn
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-06

Review 6.  Risk of postoperative recurrence and postoperative management of Crohn's disease.

Authors:  Antonino Spinelli; Matteo Sacchi; Gionata Fiorino; Silvio Danese; Marco Montorsi
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

7.  A watchful waiting approach for newly diagnosed Crohn's disease patients with an inflammatory phenotype.

Authors:  Sharif Yassin; Naomi Fliss Isakov; Yulia Ron; Nathaniel Aviv Cohen; Ayal Hirsch; Nitsan Maharshak
Journal:  Int J Colorectal Dis       Date:  2021-01-06       Impact factor: 2.571

8.  Predictive parameters for the clinical course of Crohn's disease: development of a simple and reliable risk model.

Authors:  Andreas Stallmach; Bernd Bokemeyer; Ulf Helwig; Andreas Lügering; Niels Teich; Imma Fischer; Stefan Rath; Dorothee Lang; Carsten Schmidt
Journal:  Int J Colorectal Dis       Date:  2019-08-24       Impact factor: 2.571

Review 9.  Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease.

Authors:  Ashwin N Ananthakrishnan; Hai Yun Shi; Whitney Tang; Cindy C Y Law; Joseph J Y Sung; Francis K L Chan; Siew C Ng
Journal:  J Crohns Colitis       Date:  2016-02-29       Impact factor: 9.071

10.  Treat to Target in Inflammatory Bowel Disease.

Authors:  Peter Bossuyt; Séverine Vermeire
Journal:  Curr Treat Options Gastroenterol       Date:  2016-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.